Paul C. Guest Livres

Employing accessible language throughout, this book covers the history of psychiatric research, the current state-of-the art in psychiatric practice, the physiological systems affected by psychiatric illnesses, the whole-body nature of these diseases and the impact that this aspect has on emerging biomarker discoveries. Further, it provides descriptions of the major specific psychiatric disorders and the special challenges regarding the diagnosis and treatment of each. The book concludes with insights into the latest developments in hand-held biomarker test devices, which can provide diagnostic information in less than 15 minutes in point-of-care settings. This book investigates the emerging use of biomarkers in the study of psychiatric diseases, a topic of considerable importance for a broad range of people including researchers, clinicians, psychiatrists, university students and even those whose lives are affected in some way by a psychiatric illness. The last category is hardly trivial, since a staggering one in three people worldwide show the criteria for at least one psychiatric disorder at some point in their lifetime. 

Continuous advancements in technology and insights into the complexities of neurological diseases have heightened the need for proteomic technologies that can provide potential biomarkers for better clinical management and drug development. This volume outlines the use of proteomic methods, including two-dimensional gel electrophoresis, multiplex immunoassay, liquid chromatography mass spectrometry (LC-MS), and selective reaction monitoring MS, aimed at enhancing our understanding of these diseases to ultimately improve patient care. It will appeal to clinical scientists, physicians, and pharmaceutical researchers by offering insights into the latest technologies that support the evolution of personalized medicine. Additionally, it provides detailed protocols for technical and bench biomarker scientists, making it a valuable resource for researchers as well. Each technique is presented in the context of specific neurological disorders, such as Alzheimer's disease, multiple sclerosis, autism spectrum disorders, schizophrenia, major depressive disorder, and bipolar disorder. The volume also emphasizes future research efforts focused on adapting proteomic platforms into handheld devices for point-of-care diagnostics, enabling timely results during routine medical visits.